Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA will meet to review behavior changes and psychiatric risks of Pfizer's stop-smoking drug
FDA will meet to review behavior changes and psychiatric risks of Pfizer's stop-smoking drug
FDA will meet to review behavior changes and psychiatric risks of Pfizer's stop-smoking drug
Submitted by
admin
on April 25, 2014 - 11:20am
Source:
Yahoo/AP
News Tags:
FDA
Pfizer
Chantix
smoking cessation
Headline:
FDA will meet to review behavior changes and psychiatric risks of Pfizer's stop-smoking drug
Do Not Allow Advertisers to Use My Personal information
